CD-7 Immunohistochemistry at Lahore PCR Lab

CD-7 Immunohistochemistry at Lahore PCR Lab

CD-7 Immunohistochemistry (IHC) is a highly specialized diagnostic pathology test performed to detect the presence and expression pattern of the CD7 antigen in tissue specimens. The CD7 antigen is a 40 kDa transmembrane glycoprotein and a prominent member of the immunoglobulin superfamily. It is recognized as one of the earliest cell surface markers expressed during T-cell ontogeny, appearing on pluripotent hematopoietic stem cells, lymphoid progenitor cells in the bone marrow, and early thymocytes. In healthy individuals, CD7 is consistently expressed on mature T-lymphocytes and natural killer (NK) cells, playing a vital role in T-cell activation and signal transduction.

At Lahore PCR Lab in Lahore, Pakistan, CD-7 Immunohistochemistry is utilized as a cornerstone diagnostic tool in hematopathology and oncopathology. The test works by applying highly specific monoclonal antibodies to formalin-fixed paraffin-embedded (FFPE) tissue sections. When these antibodies bind to the CD7 antigen on the cell membrane, a specialized secondary detection system and chromogen substrate are applied, producing a visible colored precipitate under a light microscope. This allows pathologists to evaluate the cellular localization, intensity, and distribution of CD7 expression.

The clinical importance of CD-7 IHC lies in its exceptional sensitivity for identifying cells of T-cell lineage. It is invaluable for distinguishing T-cell acute lymphoblastic leukemia (T-ALL) and T-cell lymphoblastic lymphoma from B-cell malignancies and other poorly differentiated neoplasms. Furthermore, evaluating CD7 expression is critical for identifying mature T-cell malignancies, such as Mycosis Fungoides and Sezary Syndrome, which are frequently characterized by an aberrant loss of this marker. By providing precise lineage identification, CD-7 IHC assists oncologists in formulating accurate diagnoses, determining prognosis, and designing targeted therapeutic strategies.

Clinical Procedure: What to Expect

Patient Preparation

Because CD-7 Immunohistochemistry is a laboratory analysis performed on tissue specimens, patient preparation depends entirely on the procedure used to obtain the tissue sample. Lahore PCR Lab recommends the following guidelines for patients and referring physicians:

• Biopsy Preparation: If a fresh tissue biopsy (such as a lymph node, skin, or bone marrow biopsy) is required, follow the specific preparation instructions provided by your surgeon or interventional radiologist. This may include fasting or adjusting blood-thinning medications.
• Archival Tissue Blocks: If the biopsy has already been performed at another facility, patients must submit the Formalin-Fixed Paraffin-Embedded (FFPE) tissue block and the corresponding hematoxylin and eosin (H&E) stained slides to Lahore PCR Lab. No direct patient preparation is required in this scenario.
• Clinical Documentation: Always provide a complete clinical history, previous pathology reports, and relevant laboratory findings (such as complete blood counts or flow cytometry results) to ensure an accurate pathological correlation.

During the Procedure

The laboratory phase of CD-7 Immunohistochemistry at Lahore PCR Lab involves a series of highly controlled, automated steps to ensure diagnostic precision:

• Specimen Sectioning: Ultra-thin sections (approximately 3 to 4 microns) are cut from the paraffin block using a precision microtome and mounted onto positively charged glass slides to prevent tissue detachment.
• Deparaffinization and Rehydration: The slides are heated and treated with clearing agents (such as xylene) and graded alcohols to remove the paraffin wax and rehydrate the tissue.
• Antigen Retrieval: To expose the CD7 epitopes masked during formalin fixation, the tissue undergoes Heat-Induced Epitope Retrieval (HIER) using specialized buffer solutions at controlled temperatures.
• Antibody Incubation: The tissue is incubated with a highly specific primary monoclonal anti-CD7 antibody, followed by a secondary polymer-based detection system.
• Visualization: A chromogen, typically Diaminobenzidine (DAB), is applied, reacting with the detection system to produce a brown membranous stain where CD7 is present. The slides are counterstained with hematoxylin, dehydrated, and coverslipped.
• Pathologist Review: A consultant pathologist examines the stained slides under a high-resolution light microscope to assess the staining pattern and formulate the diagnostic report.

When is a CD-7 Immunohistochemistry Performed?

Diagnosis of T-Cell Acute Lymphoblastic Leukemia (T-ALL)

Physicians request CD-7 IHC when evaluating patients presenting with symptoms of acute leukemia, such as severe fatigue, bone pain, bruising, and mediastinal masses. Because CD7 is the most sensitive marker for T-cell lineage, its strong expression on immature blasts helps confirm a diagnosis of T-ALL, distinguishing it from B-cell acute lymphoblastic leukemia (B-ALL) or acute myeloid leukemia (AML).

Subtyping Peripheral T-Cell Lymphomas

In patients presenting with unexplained lymphadenopathy, hepatosplenomegaly, or systemic B-symptoms (fever, night sweats, weight loss), a lymph node biopsy is performed. Pathologists utilize CD-7 IHC alongside other pan-T-cell markers (CD2, CD3, CD5) to subtype peripheral T-cell lymphomas. A key diagnostic feature of mature T-cell malignancies is the aberrant loss of CD7 expression, which helps differentiate malignant T-cells from reactive, non-neoplastic T-lymphocytes.

Evaluating Acute Myeloid Leukemia (AML) Lineage

While CD7 is primarily a T-cell marker, it can be aberrantly expressed in approximately 20% to 30% of AML cases, particularly minimally differentiated AML (FAB M0) and acute megakaryoblastic leukemia (FAB M7). Detecting CD7 expression in myeloid leukemias is clinically significant as it often correlates with specific genetic mutations and can indicate a more aggressive clinical course, helping hematologists tailor post-remission therapies.

Investigating Suspected Mycosis Fungoides and Sezary Syndrome

Dermatologists and oncologists request CD-7 IHC on skin biopsies of patients presenting with persistent, unexplained erythematous plaques or generalized erythroderma. In Mycosis Fungoides (a form of cutaneous T-cell lymphoma), the neoplastic T-cells infiltrating the epidermis typically show a marked loss of CD7 expression. Comparing the ratio of CD7-positive to CD7-negative T-cells in the skin helps establish a definitive diagnosis early in the disease course.

Monitoring Minimal Residual Disease and Phenotypic Aberrancy

Following chemotherapy or hematopoietic stem cell transplantation, CD-7 IHC is performed on follow-up bone marrow biopsies to monitor for minimal residual disease (MRD). By identifying cells that express CD7 in abnormal locations or in combination with non-lymphoid markers, pathologists can detect early signs of disease relapse before clinical symptoms manifest.

What Does a CD-7 Immunohistochemistry Detect?

CD-7 Immunohistochemistry detects several critical cellular and pathological features within tissue specimens, including:

• Strong, continuous membranous staining in normal thymocytes.
• Diffuse membranous expression in mature peripheral helper and cytotoxic T-lymphocytes.
• Moderate to strong membranous staining in natural killer (NK) cells.
• Early antigen expression in pluripotent hematopoietic stem cells within the bone marrow.
• Intense membranous positivity in precursor T-lymphoblasts, confirming T-ALL.
• Aberrant loss of CD7 expression in cutaneous T-cell lymphoma (Mycosis Fungoides).
• Loss of CD7 expression in circulating atypical lymphocytes in Sezary Syndrome.
• Aberrant CD7 expression on myeloblasts in minimally differentiated Acute Myeloid Leukemia (AML-M0).
• CD7 positivity in acute megakaryoblastic leukemia (AML-M7).
• Preservation of CD7 expression in reactive inflammatory skin conditions, helping rule out malignancy.
• Normal distribution of CD7-positive T-cells in the paracortical zones of reactive lymph nodes.
• Disruption of normal lymph node architecture by sheets of CD7-positive neoplastic cells.
• Co-expression of CD7 with other pan-T markers (CD2, CD3, CD5) in benign lymphoid proliferations.
• Discordant loss of CD7 relative to CD3 in peripheral T-cell lymphoma, not otherwise specified (PTCL-NOS).
• Variable CD7 expression in Angioimmunoblastic T-cell Lymphoma (AITL).
• Loss or dim expression of CD7 in Anaplastic Large Cell Lymphoma (ALCL).
• CD7 expression in extranodal NK/T-cell lymphoma, nasal type.
• Absence of CD7 expression in normal and neoplastic B-lineage cells (such as B-cell lymphomas).
• Cytoplasmic CD7 staining patterns in highly immature precursor cells.
• The proportion of CD7-positive tumor-infiltrating lymphocytes (TILs) in solid tumor microenvironments.
• CD7 expression in blastic plasmacytoid dendritic cell neoplasms (BPDCN).
• Clonal expansion of CD7-deficient T-cells in rare non-malignant inflammatory states.
• Diminished CD7 expression in senescent or chronically stimulated T-cell populations.
• High-intensity CD7 expression in early thymic precursor (ETP) acute lymphoblastic leukemia.
• Negative staining in classical Hodgkin Lymphoma Reed-Sternberg cells, aiding in differential diagnosis.

Turnaround Time and Report Access at Lahore PCR Lab

At Lahore PCR Lab, we understand that timely pathology results are critical for patient care and treatment planning. The turnaround time for CD-7 Immunohistochemistry is typically 3 to 5 working days. This timeframe allows our pathology team to perform precise tissue processing, antigen retrieval, staining, and a comprehensive review by our consultant pathologists. If additional immunohistochemical stains are required to complete the diagnostic panel, the reporting time may be adjusted accordingly.

Patients and referring oncologists can access diagnostic reports conveniently through the Lahore PCR Lab secure online portal. Once the report is finalized, an automated SMS notification is sent to the patient with a direct link to download the PDF report. Physical copies of the report can also be collected from our main diagnostic facility or designated collection centers across Lahore, Pakistan.

CD-7 Immunohistochemistry Findings Overview

Structure / Parameter Evaluated	Normal Findings	Possible Abnormal Findings
Thymic Lymphocytes (Thymocytes)	Strong, diffuse membranous CD7 expression	Loss of expression or abnormal maturation patterns in thymic neoplasms
Peripheral T-Lymphocytes	Membranous staining in >90% of T-cells	Aberrant loss of CD7 expression (indicative of mature T-cell lymphoma)
Natural Killer (NK) Cells	Moderate to strong membranous expression	Aberrant loss or marked overexpression in NK-cell leukemias/lymphomas
Myeloid Progenitor Cells	Negative to weak/focal expression	Aberrant strong expression (associated with AML, particularly M0 and M7 subtypes)
B-Lymphocytes	Completely negative	Aberrant expression (extremely rare; requires correlation with other lineage markers)
Lymph Node Architecture	CD7+ cells localized primarily in paracortical zones	Disruption of zones with diffuse sheets of CD7+ blasts or atypical T-cells
Epidermal T-cells (Skin Biopsy)	Sparse, scattered CD7+ intraepithelial lymphocytes	Clonal intraepidermal microabscesses showing CD7-negative atypical T-cells
Bone Marrow Trephine Biopsy	Scattered CD7+ lymphoid cells (<5% of total cellularity)	Hypercellular marrow packed with CD7+ lymphoblasts (T-ALL)

Note: Diagnostic findings should always be interpreted by a qualified healthcare professional together with the patient’s symptoms, medical history, physical examination, laboratory investigations, previous imaging studies, and other relevant clinical information. Additional investigations or specialist consultation may be recommended depending on the findings.

Why Choose Lahore PCR Lab for CD-7 Immunohistochemistry?

• Experienced Pathology Team: Our laboratory features highly qualified consultant pathologists and hematopathologists specializing in oncopathology.
• State-of-the-Art Technology: We utilize advanced automated immunohistochemistry platforms to ensure consistent and reproducible staining quality.
• Stringent Quality Control: Lahore PCR Lab adheres to strict internal and external quality assurance protocols for all diagnostic assays.
• Comprehensive Antibody Panels: We offer an extensive menu of IHC markers to provide complete diagnostic characterization in a single facility.
• Convenient Online Access: Patients and clinicians can easily view, download, and share digital reports via our secure online portal.
• Patient-Focused Care: We prioritize patient comfort and provide clear guidance throughout the sample submission process.
• Centrally Located: Our main diagnostic facility is conveniently located in Lahore, Pakistan, with multiple collection centers for easy access.
• Commitment to Accuracy: We are dedicated to delivering precise, evidence-based pathology reports to support effective clinical decision-making.